1 / 4

Monoclonal Antibody Therapeutics Market Share Value Projected to Expand by 2018-2026

Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. <br>

rushi12
Télécharger la présentation

Monoclonal Antibody Therapeutics Market Share Value Projected to Expand by 2018-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Monoclonal Antibody Therapeutics Market - Monoclonal Antibody Therapeutics Market - Size, Share, Growth, Outlook, and Opportunity Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 Analysis, 2018-2026 Monoclonal antibodies are a type of immunotherapy, which are made in a laboratory and are several copies of a single antibody. Several monoclonal antibodies to treat inflammatory, cancer, and other diseases have been approved by the U.S. Food & Drug Administration (FDA). Depending on the source, there are four types of monoclonal antibodies: Murine, Chimeric, Humanized, and Human. Murine antibodies are entirely derived from a murine source, chimeric antibodies contain variable regions from murine origin and constant regions from human origin. Humanized antibodies are derived from a human source with a small part of a mouse or rat monoclonal antibody and human antibodies are entirely derived from a human source. Monoclonal antibodies are majorly used in cancer treatment along with certain inflammatory, infectious, and other diseases. Depending upon the functions of monoclonal antibodies (for cancer) they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available monoclonal antibodies include, Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2403 Increasing drug approvals and launch of novel monoclonal antibodies for treatment of various diseases such as cancer are expected to boost the market growth over the forecast period Frequent approvals of novel monoclonal antibodies and their launches in developed economies are expected to significantly drive monoclonal antibody therapeutics market growth over the forecast period. Key players in the market have gained regulatory approvals and have launched their therapies in the market. For instance, in 2015, the U.S. FDA approved Darzalex, developed by Johnson & Johnson for multiple myeloma. Similarly, in 2017, Roche was granted accelerated approval to TECENTRIQ (atezolizumab) from the U.S FDA for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy.

  2. Ongoing research and development of monoclonal antibodies for various diseases is expected to boost growth of the global monoclonal antibody therapeutics market Introduction and supposed success of monoclonal antibodies and other biological products has spurred the interest of manufacturers in these therapies. Success of popular monoclonal antibodies such as Avastin, Herceptin, and Rituxan (revenues as US$ 6.8 Bn, US$ 7.1 Bn, and US$ 5.9 Bn respectively in 2017 globally) has spurred manufacturers’ interest in these therapies. Leading manufacturers have resorted to boosting pipeline through various ways such as merger and acquisitions, partnerships, and collaboration. In 2016, AbbVie acquired Stemcentrx thereby adding rovalpituzumab tesirine (Rova-T) to its product portfolio in oncology segment. Cancer treatment (various types) is at the forefront of the monoclonal antibody research as leading manufacturers are focused on development of these drugs for cancer treatment. For instance, manufacturers such as Amgen, Inc. (e.g. Tezepelumab and others) and Novartis International AG (e.g. Ofatumumab and others) have several monoclonal antibody programs in the pipeline. Report includes chapters which deeply display the following deliverable about industry : • Monoclonal Antibody Therapeutics Market Research Objective and Assumption • Monoclonal Antibody Therapeutics Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Monoclonal Antibody Therapeutics Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Monoclonal Antibody Therapeutics Market, By Regions • Monoclonal Antibody Therapeutics Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Monoclonal Antibody Therapeutics Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Monoclonal Antibody Therapeutics Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Monoclonal Antibody Therapeutics Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion

  3. Some of the major players operating in the global monoclonal antibody therapeutics market include, Pfizer, Inc., Novartis International AG, Amgen, Inc., Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., AbbVie, Inc., Eily, Lilly, and Company, and Bristol-Myers Squibb Company. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2403 Detailed Segmentation: Global Monoclonal Antibody Therapeutics Market, By Source: • Human • Humanized • Chimeric • Others Global Monoclonal Antibody Therapeutics Market, By Therapeutic Application: • Oncology • Autoimmune Diseases • Infectious Diseases • Hematological Disorders • Others Global Monoclonal Antibody Therapeutics Market, By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Specialty Pharmacies Global Monoclonal Antibody Therapeutics Market, By Geography: • North America • • • • Europe • Asia Pacific • Latin America • Middle East • Africa • About Coherent Market Insights

  4. Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related